Aptorum Group Enters Agreement with DiamiR Biosciences

TL;DR

APM inks deal with DiamiR Biosciences, filing 6-K for Oct 2025.

AI Summary

Aptorum Group Ltd. (APM) announced on October 15, 2025, that it has entered into an Agreement and Plan with DiamiR Biosciences Corp. This filing is a Report of Foreign Private Issuer for the month of October 2025, indicating Aptorum Group will file its annual reports under Form 20-F.

Why It Matters

This agreement signifies a potential strategic move for Aptorum Group, which could impact its future business development and market position.

Risk Assessment

Risk Level: low — The filing is a routine report and does not contain information indicating significant immediate risk.

Key Players & Entities

• Aptorum Group Ltd. (company) — Registrant
• APM (company) — Ticker symbol for Aptorum Group Ltd.
• DiamiR Biosciences Corp. (company) — Party to an agreement with Aptorum Group
• October 2025 (date) — Reporting period for the 6-K
• 17 Hanover Square London W1S 1BN, United Kingdom (location) — Principal executive office address

FAQ

Filing Documents

• ea0260603-6k_aptorum.htm (6-K) — 22KB
• ea026060301ex99-1_aptorum.htm (EX-99.1) — 262KB
• ea026060301ex99-2_aptorum.htm (EX-99.2) — 90KB
• 0001213900-25-099193.txt ( ) — 3014KB
• dimr-20250831.xsd (EX-101.SCH) — 35KB
• dimr-20250831_cal.xml (EX-101.CAL) — 60KB
• dimr-20250831_def.xml (EX-101.DEF) — 189KB
• dimr-20250831_lab.xml (EX-101.LAB) — 269KB
• dimr-20250831_pre.xml (EX-101.PRE) — 194KB
• ea0260603-6k_aptorum_htm.xml (XML) — 243KB

Forward-looking statements are subject to known

Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results could differ materially from those anticipated in forward-looking Report on Form 20-F filed with the U.S. Securities and Exchange Commission. These forward-looking statements are based on information available as of the date of this news release, and expectations, forecasts and assumptions as of that date, involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. 1

Financial Statements and Exhibits

Financial Statements and Exhibits. Exhibits . The following exhibits are attached. Exhibit Description 10.1 Merger Agreement by and between Aptorum and DiamiR, dated July 14, 2025 (incorporated by reference to the Current Report on Form 6-K filed on July 22, 2025) 99.1 Unaudited Consolidated Financial Statements as of August 31, 2025 and May 31, 2025 and for the Three Months Ended August 31, 2025 and 2024 99.2 Management's Discussion And Analysis Of Its Financial Condition And Results Of Operations as of August 31, 2025 and May 31, 2025 and for the Three Months Ended August 31, 2025 and 2024 101.INS Inline XBRL Instance Document 101.SCH Inline XBRL Taxonomy Extension Schema Document 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: October 15, 2025 Aptorum Group Limited By: /s/ Ian Huen Ian Huen Chief Executive Officer 3

View Full Filing

View this 6-K filing on SEC EDGAR